Latest news

Thumbnail image for Does your team always deliver?

Does your team always deliver?

If so, you ought to know that the 2018 PharmaTimes Clinical Researcher of the Year - The Americas  application process for teams has been made MUCH simpler this year, so if you thought you didn't have enough time to enter, think again!

10th January 2018

Thumbnail image for NICE backs wider use of MSD’s Simponi

NICE backs wider use of MSD’s Simponi

Cost regulators for therapies funded by the NHS in England and Wales have added MSD’s Simponi (golimumab) to the list of treatments recommended for severe non-radiographic axial spondyloarthritis.

10th January 2018

Thumbnail image for UCB, Amgen’s Evenity under review in Europe

UCB, Amgen’s Evenity under review in Europe

The European Medicines Agency has accepted UCB and Amgen’s submission seeking approval for use of bone-boosting drug Evenity in post-menopausal women and in men at increased risk of fracture.

9th January 2018

Thumbnail image for Shire to split operations in two

Shire to split operations in two

Shire has unveiled plans to split its operations into two separate entities - a neuroscience division and rare diseases one, and will later decide whether they should be listed independently.

9th January 2018

Thumbnail image for Axovant shares plummet on dementia drug failure

Axovant shares plummet on dementia drug failure

Shares in Axovant Sciences Ltd sank almost 50 percent after investors shrank back on new of the failure of lead drug intepirdine in a mid-stage study in patients with a particular kind of dementia.

9th January 2018

Thumbnail image for Women at risk from sub-standard heart attack care

Women at risk from sub-standard heart attack care

New research part funded by the British Heart Foundation has highlighted stark inequalities between the treatment of men and women with heart attack and the effect this is having on survival.

8th January 2018

Thumbnail image for Novo makes second move on Ablynx

Novo makes second move on Ablynx

Novo Nordisk is switching up a gear its efforts to acquire Belgian biopharma Ablynx, with a heightened offer valued at around 2.6 billion euros.

8th January 2018

Previous  --   1 2 3 4 5 6 7 8 9 10   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download